Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 10:11:4143-4151.
doi: 10.2147/CMAR.S196378. eCollection 2019.

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer

Bing-Lei Ma  1   2 , Lin Yao  1   2 , Yu Fan  1   2 , Yu Wang  1   2 , Yi-Sen Meng  1   2 , Qian Zhang  1   2 , Zhi-Song He  1   2 , Jie Jin  1   2 , Li-Qun Zhou  1   2
Affiliations

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer

Bing-Lei Ma et al. Cancer Manag Res. .

Abstract

Purpose: Radical surgery is the preferred method for local high-risk and limited progressive prostate cancer in the routine clinical setting. However, current guidelines do not recommend neoadjuvant hormone therapy (NHT). Opinions regarding NHT vary among individual clinicians. According to the experience gained at our center, we explored the benefits of NHT for patients with prostate cancer during the perioperative period in this study. Methods: In this retrospective study, we explored the perioperative benefits of NHT among 189 patients with local high-risk or limited progressive prostate cancer who underwent radical prostatectomy and divided them into two groups: the NHT group and the non-NHT group. The NHT regimens were a gonadotropin-releasing hormone (GnRH) agonist alone (3.75/11.25 mg of leuprolide or 3.6/10.8 mg of goserelin acetate), an androgen receptor antagonist (ARA) alone, or a combination of the two. The duration of treatment was <3 months, 3 to 6 months, or >6 months. Results: We found that NHT could reduce the surgery time and intraoperative hemorrhage, thus reducing the difficulty of surgery; NHT could also improve the postoperative recovery of patients. However, it did not reduce the stage of prostate cancer or positive surgical margin rate. Conclusions: Neoadjuvant therapy is optional for some patients. We believe that NHT will improve the overall prognosis of patients as progress continues in the medical field in the future.

Keywords: limited advanced; localized high-risk; neoadjuvant hormone therapy; prostate cancer; short-term benefit.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests in this work.

Figures

Figure 4
Figure 4
Change of clinical and pathological stage (61 ≤ age ≤70 years).
Figure 1
Figure 1
Reduction magnitude of PSA level and prostate volume.
Figure 2
Figure 2
Change of clinical and pathological stage.
Figure 3
Figure 3
Change of clinical and pathological stage (age ≤60 yea).
Figure 5
Figure 5
Change of clinical and pathological stage (age >70 years).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. D‘Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974. - PubMed
    1. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol. 2018;199(3):990–997. doi:10.1016/j.juro.2018.01.002 - DOI - PubMed
    1. Mottet N, Bellmunt J, Briers E et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. Eur Assoc Urol; 2018. Available from: http://uroweb.org/guideline/prostate-cancer. - PubMed
    1. NCCN clinical practice guidelines in oncology prostate cancer version 4; 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed February15, 2018.
    1. Schulman CC, Debruyne FM, Forster G, et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol. 2000;38:706–713. doi:10.1159/000020366 - DOI - PubMed

LinkOut - more resources